艾迪注射液联合GP方案对晚期非小细胞肺癌患者的疗效及对血清VEGF表达的影响

目的探讨艾迪注射液联合吉西他滨和顺铂（GP）方案治疗晚期非小细胞肺癌（NSCLC）的近期疗效,以及对患者血清血管内皮生长因子（VEGF）水平的影响。方法将80例晚期NSCLC患者随机分为观察组（40例）和对照组（40例）,观察组给予艾迪注射液联合GP方案治疗,对照组患者则仅给予GP方案化疗;观察并对比两组患者近期疗效和血清VEGF水平的变化。结果经两周期全身化疗后,观察组临床获益率（CBR）为87.5%,明显高于对照组的67.5%,差异有统计学意义（P〈0.05）;两组患者血清VEGF水平均较治疗前明显降低,差异有统计学意义（P〈0.05）,其中以观察组患者降低更为明显,两组比较差异有统计学意义（P〈0.05）。结论艾迪注射液联合GP方案可以有效提高晚期NSCLC患者的临床获益率,并且显著降低其血清VEGF水平,从而提高化疗效果。

Efficacy of Aidi Injection combined with GP regimen in patients with advanced non-small cell lung cancer and the impact on expression of serum VEGF

Objective To explore term efficacy of Aidi Injection combined with gemcitabine and cisplatin(GP) regimen in advanced non-small cell lung cancer(NSCLC),and serum VEGF levels of patients with lung cancer.Methods 80 cases of patients with advanced NSCLC were randomly divided into observation group(40 cases) and control group(40 cases),observation group were treated with Aidi Injection combined with GP regimen,but control group were only given the GP regimen chemotherapy.The changes in short-term effect of two groups of patients and serum VEGF levels were observed.Results After two cycles of systemic chemotherapy,clinical benefit rate(CBR) of the observation group was 87.5%,significantly higher than 67.5% of control group(P < 0.05);two groups of serum VEGF level than before treatment was significantly lower,the difference was statistically significant(P < 0.05).Conclusion Aidi Injection combined with GP regimen can effectively improve the clinical benefit rate of patients with advanced NSCLC,and significantly reduce serum levels of VEGF,thereby increasing the effectiveness of chemotherapy.